Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by SrPlataon Oct 27, 2021 8:16pm
240 Views
Post# 34056912

Steps on getting to $20 USD

Steps on getting to $20 USDFirst off I realize we are a long way to $20, Yes I know that first we have to get to $3,4,5 etc first and I am not looking for it overnight (unless they is a buyout)

First step  Get Peer review from independent 3rd party on P2 data stock goes to $3to $4
Second step Release P2 trial data if shows no safety issues and efficacy, like I believe it will $5 to $6
Third Step Health Canada gives go ahead to enter P3 $6 to $7, This is assuming they have no adverse issues with the data
Fourth Step  Do nationwide media campaighn to get the out IE give CEO and CMO give interviews in Canada and Possibly in US on Financial channels. They did this for P2 rollout why not a bigger one for P3 . $8 to $9
Fifth Step  This would be Wall Street putting out research on Arch Biopartners, This would open up a whole new audience who has not heard of Arch and the story with a higher price target $10 $12
Sixth Step   Assuming Wall St is covering Arch as noted above then they put out an offering to raise capital for a P3 for Kidneys (Which is a lot bigger worldwide market than Lungs) some estimates $20 billion. I have been told that Wall St has been looking for a bio tech that can adddress this huge market of AKI. $13 to $15 
Seventh Step If all the above happens then we will get institutionall sponsorship IE are market cap will be such that we will be included in some of the indexes like Russell 2000 also ETF specific Bio Tech, also we will meet criteria for Mutual Fund ownership etc. $16 to $18 
Eighth Step P3 trial data is showing great results $19 to $20
Ninth Step  Big Pharma has to have us WE NAME OUR PRICE

If you add in that we are under the Radar of most investors and our tight share structure and where we trade now. I may be conservative or aggressive on the above steps. First step has to happen or the other steps won't

This is not going to happen overnight and willl take some time. Anything can happen feel free to add comments and criticism of the above
<< Previous
Bullboard Posts
Next >>